Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2011 Jul;26(7):954-8.
doi: 10.3346/jkms.2011.26.7.954. Epub 2011 Jun 20.

Pancreatic endocrine tumors: a report on a patient treated with sorafenib

Affiliations
Case Reports

Pancreatic endocrine tumors: a report on a patient treated with sorafenib

Hee Kyoung Jeong et al. J Korean Med Sci. 2011 Jul.

Abstract

A 31-yr-old man with abdominal pain was diagnosed with a pancreatic endocrine tumor and multiple hepatic metastases. Despite optimal treatment with interferon alpha, a somatostatin analog, local therapy with high-intensity focused ultrasound ablation for multiple hepatic metastases, and multiple lines of chemotherapy with etoposide/cisplatin combination chemotherapy and gemcitabine monotherapy, the tumor progressed. As few chemotherapeutic options were available for him, sorafenib (800 mg/day, daily) was administered as a salvage regimen. Sorafenib was continued despite two episodes of grade 3 skin toxicity; it delayed tumor progression compared to the previous immunotherapy and chemotherapy. Serial computed tomography scans showed that the primary and metastatic tumors were stable. Thirteen months after beginning targeted therapy, and up to the time of this report, the patient is well without disease progression. We suggest that sorafenib is effective against pancreatic endocrine tumors.

Keywords: Chemotherapy; Neuroendocrine Tumors; Sorafenib.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Radiologic images of pancreatic, non-functioning, well-differentiated, endocrine carcinoma and multiple liver metastases. (A) Contrast enhanced CT scan (02/19/2009) shows a 6.8 cm lobulated mass in the uncinated process of the pancreas (arrow). The tumor shows focal cystic and necrotic areas, and heterogeneous enhancement. Multiple hematogenous metastases are also noted (arrowheads). (B) Follow-up contrast enhanced CT scan (03/31/2009) shows the lobulated mass in the uncinated process measuring 5.4 cm in maximal diameter. A comparison with the previous CT scan (A) reveals interval partial regression of the primary tumor mass in the uncinate process (arrow) and hematogenous hepatic metastases (arrowheads).
Fig. 2
Fig. 2
Pathologic findings of the pancreatic, non-functioning, well-differentiated, endocrine carcinoma. (A) Histologic examination shows that the tumor cells were arranged in trabeculae and solid nests separated by a fibrous or loose fibrovascular stroma (H&E, × 100). (B) All tumor cells were large and polygonal in shape and had abundant, eosinophilic, and finely granular cytoplasm containing round to oval nuclei with finely stippled chromatin (H&E, × 400). (C) Tumor cells were strongly positive for chromogranin (IHC, × 400).

Similar articles

References

    1. O'Grady HL, Conlon KC. Pancreatic neuroendocrine tumours. Eur J Surg Oncol. 2008;34:324–332. - PubMed
    1. Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, Klimstra DS. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002;20:2633–2642. - PubMed
    1. Costa F, Domenichini E, Garavito G, Medrano R, Mendez G, O'Connor J, Rojas W, Torres S, Younes RN, Delle Fave G, Oberg K. Management of neuroendocrine tumors: a meeting of experts from Latin America. Neuroendocrinology. 2008;88:235–242. - PubMed
    1. Delaunoit T, Neczyporenko F, Rubin J, Erlichman C, Hobday TJ. Medical management of pancreatic neuroendocrine tumors. Am J Gastroenterol. 2008;103:475–483. - PubMed
    1. Warner RR. Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology. 2005;128:1668–1684. - PubMed

Publication types

MeSH terms